Spruce Biosciences to Submit FDA Application for Tralesinidase Alfa, a Treatment for Sanfilippo Syndrome, in Q4.
Successful Pre-BLA Meeting and Resolution of Regulatory Uncertainty
Spruce Biosciences has completed a successful pre-BLA (pre-approval) meeting with the U.S. Food and Drug Administration (FDA), clarifying the regulatory pathway. The FDA concluded that the company's analytical comparability strategy for the drug substance and finished pharmaceutical product is valid. This marks a significant milestone by fully resolving the uncertainty that had delayed the approval timeline from Q1 to Q4 of 2026 due to prior manufacturing data requests. With clinical efficacy already validated, the company has now cleared the final regulatory hurdle.
Commercialization Initiated Through Contract Manufacturing and CMC Advancement
Spruce has successfully transitioned production to a global contract development and manufacturing organization (CDMO), bringing commercial batch production onto track. To strengthen the manufacturing quality and process control (CMC) critical for biopharmaceutical approvals, the company is simultaneously advancing large-scale bioreactor evaluations and a multi-source supplier strategy. This proactive approach aims to prevent potential supply bottlenecks post-approval and increase the likelihood of commercial success, demonstrating real control over manufacturing risks previously deemed difficult to quantify by analysts.
Revival from Bankruptcy to Core Pipeline
The drug in question, tralesinidase alfa, was originally a licensed enzyme replacement therapy (ERT) candidate from Allievex to BioMarin. However, Allievex failed to overcome regulatory hurdles and entered bankruptcy proceedings in 2023, putting the asset at risk of being abandoned. Spruce acquired the asset through bankruptcy liquidation, inheriting existing obligations to BioMarin without upfront payments. This strategic move proved to be a turning point for Spruce, which had previously faced existential threats due to clinical pipeline failures.
Securing First-in-Class Status for Sanfilippo Syndrome Type B
Tralesinidase alfa is an innovative therapy that replaces the deficient N-acetyl-alpha-glucosaminidase (NAGLU) enzyme to prevent the toxic accumulation of heparan sulfate in brain cells. As no FDA-approved treatment currently exists for Sanfilippo Syndrome Type B (MPS IIIB), the drug is positioned for a unique market position. Although it is an ultra-rare disease affecting approximately one in 200,000 newborns, its strong pricing power is expected to drive annual peak sales exceeding $300 million. A broad patent portfolio secured until 2038 will further ensure long-term cash flow generation.
Spruce Biosciences (SPRB)'s tralesinidase alfa (TA-ERT) is on track for a BLA submission in Q4 2026, giving it short-term regulatory momentum and positioning it as a likely first-mover to drive the $2.82 billion global Sanfilippo Syndrome (MPS III) market growth by 2036. From an investor perspective, the asset acquisition structure—without upfront payments—minimizes financial burden while offering high commercial value through potential peak sales exceeding $300 million and a long-term patent exclusivity period until 2038. From a research and industry standpoint, the clinical validation of a novel mechanism involving direct intracerebrospinal administration of a fusion protein to overcome the blood-brain barrier (BBB) by delivering the deficient NAGLU enzyme holds significant scientific merit. Additionally, its first-in-class status provides a strategic advantage in the competitive landscape, particularly against JCR Pharmaceuticals' JR-446 and other AAV-based gene therapy pipelines.